148 related articles for article (PubMed ID: 25006129)
21. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
22. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
23. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia.
Obermann EC; Arber C; Jotterand M; Tichelli A; Hirschmann P; Tzankov A
Ann Hematol; 2010 Jul; 89(7):663-9. PubMed ID: 20066533
[TBL] [Abstract][Full Text] [Related]
24. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Zhang X; Li B; Yu J; Dahlström J; Tran AN; Björkholm M; Xu D
Ann Hematol; 2018 Jan; 97(1):63-72. PubMed ID: 29080039
[TBL] [Abstract][Full Text] [Related]
25. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
Takami M; Katayama K; Noguchi K; Sugimoto Y
Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
[TBL] [Abstract][Full Text] [Related]
29. Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding.
Desterke C; Hugues P; Hwang JW; Bennaceur-Griscelli A; Turhan AG
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517078
[TBL] [Abstract][Full Text] [Related]
30. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
31. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
[No Abstract] [Full Text] [Related]
32. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Ribeiro D; Melão A; van Boxtel R; Santos CI; Silva A; Silva MC; Cardoso BA; Coffer PJ; Barata JT
Blood Adv; 2018 Sep; 2(17):2199-2213. PubMed ID: 30185437
[TBL] [Abstract][Full Text] [Related]
33. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
34. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
Goldberg L; Tijssen MR; Birger Y; Hannah RL; Kinston SJ; Schütte J; Beck D; Knezevic K; Schiby G; Jacob-Hirsch J; Biran A; Kloog Y; Marcucci G; Bloomfield CD; Aplan PD; Pimanda JE; Göttgens B; Izraeli S
Blood; 2013 Oct; 122(15):2694-703. PubMed ID: 23974202
[TBL] [Abstract][Full Text] [Related]
35. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
36. CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.
Fujiwara SI; Muroi K; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Ozawa K
Hematology; 2017 Jul; 22(6):347-353. PubMed ID: 28097942
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.
Giraud F; Bourhis M; Ebrahimi E; Herfindal L; Choudhury RR; Bjørnstad R; Døskeland SO; Anizon F; Moreau P
Bioorg Med Chem; 2015 Nov; 23(22):7313-23. PubMed ID: 26526744
[TBL] [Abstract][Full Text] [Related]
38. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
39. Aurora kinase inhibitor restrains STAT5-activated leukemic cell proliferation by inducing mitochondrial impairment.
Wang JX; Zhang L; Huang ZW; Zhang XN; Jiang YY; Liu FJ; Long L; Xue MJ; Lu G; Liu Q; Long ZJ
J Cell Physiol; 2020 Nov; 235(11):8358-8370. PubMed ID: 32239704
[TBL] [Abstract][Full Text] [Related]
40. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]